Review Article
Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis
Table 1
Basic characteristics of included studies.
| | Author | Year | Patient source | Sample size | TIGIT + | Cancer type | Method | Expression location | Cut-off value | Outcome | M/U | HR ratio | NOS |
| | Zhao JJ | 2018 | Chinese | 154 | 76 (49.4%) | ESCC | IHC | TIL | Median level | OS | M | Reported | 8 | | Tang W | 2019 | Chinese | 441 | 343 (77.8%) | GC | IHC | Tumor cell | >5% positivity cell | OS | M | Reported | 8 | | Xu Y | 2019 | Chinese | 60 | 21 (35%) | SCLC | IHC | Tumor cell | Median level | OS | U | Survival curve | 6 | | Lee WJ | 2020 | Korea | 124 | 52 (41.9%) | Melanoma | IHC | Tumor cell | ≥20% positivity cell | OS/PFS | U | Survival curve | 7 | | Sun Y | 2020 | Chinese | 334 | 204 (61.1%) | LUAD | IHC | TIL | ≥5% positivity cell | OS/PFS | M | Reported/survival curve | 7 | | Zhao K | 2020 | Chinese | 114 | 74 (64.9%) | PSCCE | IHC | Tumor cell | ≥5% positivity cell | OS/PFS | M | Reported/survival curve | 8 | | Zhou X | 2020 | Chinese | 60 | 21 (35%) | CRC | IHC | Tumor cell | | OS/DFS | M | Reported | 8 | | Liang R | 2021 | Chinese | 139 | 40 (28.8%) | CRC | IHC | Tumor cell | Median level | OS/RFS | U | Survival curve | 6 |
|
|
OS: overall survival; PFS: progress-free survival; DFS: disease-free survival; RFS: recurrence-free survival; U: univariate; M: multivariate; TIL: tumor infiltrating lymphocyte; IHC: immunohistochemistry; LUAD: lung adenocarcinoma; GC: gastric cancer; SCLC: small cell lung cancer; ESCC: esophageal squamous cell carcinoma; PSCCE: primary small cell carcinoma of the esophagus; CRC: colorectal cancer.
|
